阿托伐他汀对不稳定型心绞痛患者血浆C―反应蛋白和血脂水平影响.docVIP

阿托伐他汀对不稳定型心绞痛患者血浆C―反应蛋白和血脂水平影响 　　[摘要] 目的 研究阿托伐他汀对不稳定型心绞痛患者血浆C-反应蛋白和血脂水平的影响。 方法 选取2015年12月～2016年12月我院收治的不稳定型心绞痛患者70例进行观察，按照随机数字表法随机分为两组，每组35例。两组患者均予常规治疗，观察组同时加用阿托伐他汀40 mg，每天3次，持续4周。 结果 治疗后，观察组患者的hs-CRP水平为（2.3±0.6） mg/L，与对照组患者治疗后的hs-CRP水平比较，存在显著性差异（P0.05）。治疗后，观察组患者的TC为（4.12±0.97）mmol/L、TG为（1.58±0.49）mmol/L、LDL-C为（2.82±0.53）mmol/L、HDL-C为（1.53±0.53）mmol/L，对照组患者的TC 为（4.89±1.28）mmol/L、TG为（1.66±0.42）mmol/L、LDL-C为（3.07±0.64）mmol/L、HDL-C为（1.31±0.42）mmol/L，两组比较，存在显著性差异（P0.05）。 结论 阿托伐他汀能显著降低不稳定型心绞痛患者血浆C-反应蛋白，改善血脂各项指标，从而显著提高临床疗效。 　　[关键词] 阿托伐他汀；不稳定型心绞痛；血浆C-反应蛋白；血脂；hs-CRP 　　[中图分类号] R541.4 [文献标识码] B [文章编号] 1673-9701（2018）02-0034-03 　　[Abstract] Objective To study the effect of atorvastatin on plasma C-reactive protein and serum lipids in patients with unstable angina pectoris. Methods A total of 70 patients with unstable angina pectoris admitted in our hospital from December 2015 to December 2016 were selected and randomly divided into two groups according to random number table， with 35 cases in each group. Both groups were given routine treatment. The observation group was also given atorvastatin 40 mg， 3 times a day for 4 weeks. Results After treatment， the level of hs-CRP in the observation group was （2.3±0.6） mg/L， which was significantly different from that in the control group（P0.05）. After treatment， the TC of observation group was（4.12±0.97）mmol/L， TG was（1.58±0.49）mmol/L， LDL-C was（2.82±0.53） mmol/L and HDL-C was（1.53± 0.53） mmol/L. The TC of control group was （4.89±1.28） mmol/L， TG was （1.66±0.42） mmol/L， LDL-C was （3.07±0.64） mmol/L and HDL-C was（1.31±0.42） mmol/L. There were significant differences in the TC， TG， LDL-C and HDL-C between the two groups（P0.05）. Conclusion Atorvastatin can significantly reduce the plasma C-reactive protein in patients with unstable angina and improve various indicators of blood lipids， thereby significantly improving the clinical efficacy. 　　[Key words] Atorvastatin； Unstable angina； Plasma C-reactive protein； Lipid； hs-CRP 　　不?定型